fluticasone propionate and salmeterol

FDA Drug Profile — Fluticasone Propionate and Salmeterol DISKUS, Wixela Inhub, fluticasone propionate and salmeterol, Fluticasone Propionate and Salmeterol, ADVAIR DISKUS

Drug Details

Generic Name
fluticasone propionate and salmeterol
Brand Names
Fluticasone Propionate and Salmeterol DISKUS, Wixela Inhub, fluticasone propionate and salmeterol, Fluticasone Propionate and Salmeterol, ADVAIR DISKUS
Application Number
NDA021077
Sponsor
REMEDYREPACK INC.
NDC Codes
35
Dosage Forms
POWDER
Routes
RESPIRATORY (INHALATION)
Active Ingredients
FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE

Indications and Usage

1 INDICATIONS AND USAGE ADVAIR DISKUS is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: • Twice-daily treatment of asthma in patients aged 4 years and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). ( 1.2 ) Important limitation of use: Not indicated for relief of acute bronchospasm. ( 1.1 , 1.2 ) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. ADVAIR DISKUS should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta 2 -adrenergic agonist (LABA). Important Limitation of Use ADVAIR DISKUS is NOT indicated for the relief of acute bronchospasm. 1.2 Maintenance Treatment of Chronic Obstructive Pulmonary Disease ADVAIR DISKUS 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS 250/50 is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. ADVAIR DISKUS 250/50 twice daily is the only approved dosage for the treatment of COPD because an efficacy advantage of the higher strength ADVAIR DISKUS 500/50 over ADVAIR DISKUS 250/50 has not been demonstrated. Important Limitation of Use ADVAIR DISKUS is NOT indicated for the relief of acute bronchospasm.